8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Feb 3, 2026·SEC
Aytu BioPharma, Inc.(AYTU)Earnings, Financials & Key Ratios
AYTU•NASDAQ
$2.25
Price updated Jul 7, 2026
AboutAytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.Show more
- Revenue$66M+1.8%
- EBITDA-$2M-147.7%
- Net Income-$14M+14.4%
- EPS (Diluted)-2.16+24.5%
- Gross Margin69.04%-8.3%
- EBITDA Margin-3.69%-146.9%
- Operating Margin-11.79%-383.1%
- Net Margin-20.43%+15.9%
- ROE-58.1%-23.0%
AYTU Price & Volume
Aytu BioPharma, Inc. (AYTU) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Challenges Operational Viability
Investment Thesis • Updated 2026Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Persistent operating cash burn
Key Thesis Takeaways
- Aytu BioPharma faces a challenging outlook as its core ADHD and specialty portfolio struggles to maintain market share, evidenced by a revenue decline to $12.4M in 2026Q3 from $18.7M in 2024Q2.
- The company's inability to achieve operating scale, highlighted by a -32.7% operating margin in 2026Q3, suggests that its current cost structure remains misaligned with its commercial output.
- Investors should monitor the company's reliance on a $42.5M goodwill balance, which represents 38% of total assets, as persistent operating losses may necessitate future impairment charges.
Verdict Logic
the company's inability to generate consistent operating cash flow, combined with a net margin of -45.3% in 2026Q3, suggests significant ongoing risk to shareholder equity.
AYTU Growth Metrics
Aytu BioPharma, Inc. (AYTU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years73.94%
5 Years19.16%
3 Years-11.78%
TTM-18.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2177.79%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-535.74%
Return on Capital
10 Years-70.95%
5 Years-35.52%
3 Years-13.29%
Last Year-13.3%
AYTU Recent Earnings
Aytu BioPharma, Inc. (AYTU) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.53-19.5%
$0.44
Rev
$12M+3.0%
$12M
Q1 2026
Feb 3, 2026Metric
Actual
Est
EPS
$1.05-303.8%
$0.26
Rev
$15M+24.9%
$12M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.08-33.3%
$0.06
Rev
$14M+10.2%
$13M
Q4 2025
Sep 23, 2025Metric
Actual
Est
EPS
$0.26-1200.0%
$0.02
Rev
$15M-15.5%
$18M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.53vs $0.44-19.5% | $12Mvs $12M+3.0% |
| Q1 2026 | Feb 3, 2026 | $1.05vs $0.26-303.8% | $15Mvs $12M+24.9% |
| Q4 2025 | Nov 13, 2025 | $0.08vs $0.06-33.3% | $14Mvs $13M+10.2% |
| Q4 2025 | Sep 23, 2025 | $0.26vs $0.02-1200.0% | $15Mvs $18M-15.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Aytu BioPharma, Inc. (AYTU)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.25 | $18.22M | -1.04 | 1.84% | -20.43% | -58.1% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $4.75 | $192.85M | 3.89 | 36.55% | -19.55% | -3.39% | — | |
| $23.50 | $151.86M | -4.96 | -5% | -34.94% | -38.72% | — | |
| $11.19 | $1.55B | -1.09 | -2.75% | -43.5% | -50.65% | — | |
| $36.44 | $1.18B | 21.06 | 23.62% | 9.41% | 26.74% | — |
Compare AYTU vs Peers
Aytu BioPharma, Inc. (AYTU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AYTU SEC Filings & Documents
Aytu BioPharma, Inc. (AYTU) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when AYTU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AYTU Frequently Asked Questions
Aytu BioPharma, Inc. (AYTU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Aytu BioPharma, Inc.'s revenue?
Aytu BioPharma, Inc. (AYTU) reported $56.6M in revenue for fiscal year 2025.
How fast is Aytu BioPharma, Inc. growing?
Aytu BioPharma, Inc. (AYTU) grew revenue by 1.8% over the past year. Growth has been modest.
Is AYTU profitable?
Aytu BioPharma, Inc. (AYTU) reported a net loss of $34.1M for fiscal year 2025.
Dividend & Returns
What is AYTU's return on equity?
Aytu BioPharma, Inc. (AYTU) has a return on equity (ROE) of -58.1%. Negative ROE indicates the company is unprofitable.
What is Aytu BioPharma, Inc.'s free cash flow?
Aytu BioPharma, Inc. (AYTU) generated $1.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.